p53 immunohistochemistry on 39.4% with a sensitivity of 98.5% to detect p53abn (99.6% negative predictive value). Cytologic features including tumor giant cells, smudged chromatin, cherry-red/macronucleoli, and atypical mitoses accurately predicted p53abn. In 7/292, p53abn upgraded ESGO risk groups (2 to intermediate-risk, 5 to high-risk). EEC12/stage IA patients had an excellent cause-specific 5-year survival of 98.5%.

Conclusions Pathologists can select cases for p53 testing with high sensitivity and low risk of false negativity. Molecular characterization of endometrial carcinomas has great potential to refine ESGO risk classification for a small subset but offers little value for approximately half of endometrial carcinomas, namely, EEC12/stage IA.

EPV104/#228

EMERGING IMMUNOTHERAPY PARADIGMS IN ADVANCED ENDOMETRIAL CANCER: THE EFFECT OF ONLINE EDUCATION ON CLINICIAN KNOWLEDGE AND CONFIDENCE

¹G Fisher*, ¹A Furedy, ¹J Vandenbroucq, ²N Colombo. ¹Medscape, Medical Education, London, UK; ²Instituto Europeo di Oncologia, Department of Gynecology, Milan, Italy

10.1136/ijgc-2021-IGCS.174

Objectives This study determined whether online continuing medical education (CME) could improve the knowledge of oncologists (oncs) and obstetricians/gynaecologists (obs/gyns) regarding the rationale and evidence for immunotherapy paradigms in advanced endometrial cancer.

Methods A 30-minute online video lecture was launched for physicians outside the USA August 2020 with data collected to November 2020. Educational effect assessed with repeated-pairs pre-/post-activity- individual participants serving as own control. 3 multiple-choice, knowledge questions and 1 self-efficacy, 5-point Likert scale confidence question were analyzed. Chi-squared test assessed pre- to post-activity change (5% significance level, $P < .05$). Magnitude of change in total number of correct responses overall, and for each question, determined with Cramer's V ($< .06$ =Modest, 0.06 – 0.15 =Noticeable, 0.16 – 0.26 =Considerable, $> .26$ =Extensive).

Results 142 obs/gyns and 60 oncs completed pre- and post-activity questions. Positive educational effect was observed for obs/gyns (noticeable effect, $V = .092$, $P < .01$; average% of correct responses increasing from 33 to 42%) and oncs (noticeable effect, $V = .150$, $P = .0043$; average% of correct responses increasing from 47 to 62%). Increases in correct responses post-activity seen for questions on response to 2nd line chemotherapy (% relative improvement, obs/gyn: 23%, oncs: 22%), rationale for immunotherapy (obs/gyns: 24%, oncs: 72%), data for the dostarlimab GARNET trial (obs/gyns: 36%, oncs: 21%). Confidence in knowledge of the evidence for immunotherapy strategies increased post-activity (total average confidence shift: 27% obs/gyns and 40% oncs). Overall, 22% of learners' responses were improved and 39% of learners' responses were reinforced.

Conclusions This online CME activity resulted in a positive educational impact for both clinical specialties. However, education gaps remained evident post-activity.

EPV105/#237

COMBINATION TARGETED TREATMENT WITH MEK AND PAN-ERBB INHIBITORS ENHANCES ANTITUMOR ACTIVITY IN ERBB AMPLIFIED EX-VIVO SEROUS ENDOMETRIAL CANCER CELLS

¹A Larish*, ²W-H Lin, ³J Smadbeck, ³S Sotiriou, ³J Cheville, ¹F Harris, ¹R Feathers, ¹J Lynch, ⁴A Kumar, ⁵M Block, ¹L Jones, ¹G Karagouga, ¹A Mccune, ⁵A Mansfield, ³S Murphy, ⁴A Mariani, ³G Vasmatazis, ²P Anastasiadis, ⁵J Weroha. ¹Mayo Clinic, Obstetrics and Gynecology, Rochester, USA; ²Mayo Clinic, Department of Laboratory Medicine and Pathology, Jacksonville, USA; ³Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, USA; ⁴Mayo Clinic, Division of Gynaecologic Surgery, Department of Obstetrics and Gynaecology, Rochester, USA; ⁵Mayo Clinic, Medical Oncology, Rochester, USA

10.1136/ijgc-2021-IGCS.175

Objectives ERBB pathway alterations present therapeutic targets in high grade endometrial cancer (EC), but efficacy can be limited by persistent co-activation of other ERBB binding partners. The efficacy of dual-inhibition MEK+pan-ERBB or BET+pan-ERBB in an ERBB2/ERBB3 amplified EC was investigated via 3D microcancer ex-vivo cell assay.

Methods Tumor was prospectively collected from a patient with stage IIIc1 serous EC. Whole exome, mRNA, and Mate-Pair genomic characterization was performed. Tumor cells were grown in 3D culture and subjected to titrating drug treatments. Cell viability was determined by the CellTiter-Glo Luminescent Assay. Data transformation and dose-response curves were generated using GraphPad PRISM using the variable slope model. CalcuSyn software with the Chou-Talalay method analyzed drug interactions and synergy. Afatinib, binimetanib, and JQ1 were used to inhibit pan-ERBB, MEK1/2, BET, respectively. For translational relevance, inhibitory effect was defined as percent reduction in ATP from baseline at the

Abstract EPV105/#237 Figure 1 Microcancer ex vivo exposure to MEK+pan-ERBB inhibitors. Dose response curves of single and combination treatments (left) were 10-fold titrated across 8 log doses for each agent. The highest concentration (i.e. fraction of full (FoF)=1) of afatinib, binimetanib and afatinib+JQ1 was 3 μ M, 10 μ M, and 50 μ M, respectively. The physiologically achievable concentration of afatinib is indicated (dotted lines). A combination index (CI, right) was used to assess synergy with afatinib+binimetanib and afatinib+JQ1 as shown by Fa-CI plots.